Chimeric antigen receptor (CAR) T-cell therapy has been used for the treatment of hematological malignancies, but oncologists have been using it less often due to the loss of therapeutic effectiveness ...

VANCOUVER, British Columbia, October 16, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company ...

A novel bispecific chimeric antigen receptor T-cell therapy appeared safe and effective for younger patients with relapsed or refractory acute lymphoblastic leukemia, according to the results of a ...

Philadelphia, January 4, 2022—Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering ...

Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study The frequency and intensity of antigen expression varies with ...

Ideally an MRD assay would also be applied to pretreatment/diagnostic samples, in order to ensure that each patient is suitable for monitoring with the specific assay ...

Please provide your email address to receive an email when new articles are posted on . An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity ...

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy. The toxicity profile of chimeric antigen receptor (CAR) T ...

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--First sentence of release should read: "...has been accepted by the China National Medical Products Administration (NMPA)..." (instead of "...has ...

Therapy consisted of a single-agent phase (epratuzumab 360 mg/m 2 /dose intravenously twice weekly × four doses), followed by four weekly doses of epratuzumab in combination with standard reinduction ...

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M CD22 nanobody binder offers potential advantages compared to ...